Lundbeck Research USA, Inc. Company Profile

23:33 EDT 24th March 2018 | BioPortfolio

Now that scientists have mapped the human genome, new opportunities exist for developing drugs that exclusively target specific receptors associated with the symptoms and causes of a disease.Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders. Lundbeck Research USA uses this discovery model to pursue novel treatments for CNS diseases. Our talented scientists have achieved influential discoveries in genomics (the cloning of genes) and functional genomics (the identification of a given receptor’s physiological function), making us a world leader in G Protein-Coupled Receptor (GPCR) discovery research.
As the Research Center of Excellence for Depression and Anxiety in the United States we support our parent company, H. Lundbeck A/S. A global company headquartered in Denmark, Lundbeck is a world leader in the development of pharmaceuticals for psychiatric and neurological disorders. Research and development efforts have recently resulted in the successful development of Cipralex ® (escitalopram) – the first compound of the next-generation selective serotonin reuptake inhibitors (SSRIs).
The scientific expertise at Lundbeck Research USA will ensure the continuation of a rich pipeline of drug discovery candidates for H. Lundbeck A/S.


215 College Road
New Jersey
United States of America


Phone: 1 201 261 1331
Fax: 1 201 261 0623

News Articles [80 Associated News Articles listed on BioPortfolio]

Lundbeck targets 2020 for development of partnered schizophrenia candidate

Lundbeck has acquired an exclusive license to a research program aimed at a novel approach to treating…

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will p...

H. Lundbeck A/S: Lundbeck increases its share capital by 116,330 shares (0.0585 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 2017-11-21 11:28 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 21 November 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 581,6...

Lundbeck Signs Near €1Bn Acquisition of Swiss Parkinson’s Biotech

Lundbeck is acquiring Prexton Therapeutics in a deal that could reach up to €905M if the Swiss company’s Parkinson’s treatment proves successful.  Danish pharma Lundbeck has decided to ...

H. Lundbeck A/S: Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 17 November 2017 - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons close...

H. Lundbeck A/S: Changes to Lundbeck's Executive Management

Valby, Denmark, 2017-10-30 20:48 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 30 October 2017 - H. Lundbeck A/S (Lundbeck) today announced changes to its Executive Management team. Following the resigna...

H. Lundbeck A/S: Lundbeck's Brintellix approved in China

Brintellix is now approved for the treatment of Major Depressive Disorder in China. Launch is expected to commence in Q2 2018. Valby, 2017-12-04 07:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundb...

H. Lundbeck A/S: Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

-- Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones -- Foliglurax is a first-in-class t...

Drugs and Medications [79 Associated Drugs and Medications listed on BioPortfolio]

La mer the treatment fluid foundation [MAX HUBER RESEARCH LAB INC]

Neoprofen [Lundbeck Inc.]

These highlights do not include all the information needed to use NeoProfen safely and effectively. See full prescribing information for NeoProfen. NeoProfen (ibuprofen lysine) Injection for intraveno...

Alco-san instant skin sanitizer [Mid-American Chemical Research Corporation]


Sunscreen [CRC (Cosmoceutical Research Center)]


Vionexus [Metrex Research]

VioNexus No Rinse Spray

PubMed Articles [675 Associated PubMed Articles listed on BioPortfolio]

Adding to the Truth of the Matter: The Case for Qualitative Research.

The purpose of this column is to discuss the impact that qualitative research has on translational research, whose aim is to improve the health and well-being of individuals. To that end, rigorous qua...

Improving the process of research ethics review.

Research Ethics Boards, or Institutional Review Boards, protect the safety and welfare of human research participants. These bodies are responsible for providing an independent evaluation of proposed ...

Is the Right Research Being Conducted to Advance Knowledge about Breast Reconstruction? An Analysis of the Research Pipeline.

It has been estimated that up to 85 percent of research is of limited value or wasted, in part because of the wrong research questions being addressed. In this study, the authors identified research g...

Research protocol for the Picture Talk Project: a qualitative study on research and consent with remote Australian Aboriginal communities.

Research with Indigenous populations is not always designed with cultural sensitivity. Few publications evaluate or describe in detail seeking consent for research with Indigenous participants. When p...

Clinical Research Nursing: Development of a Residency Program

Clinical research nurses are essential in the coordination of clinical trials and the management of research participants. Without a stable, knowledgeable research nurse workforce, the conduct of rese...

Clinical Trials [1008 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Research Participants' Views on the Ethics of Clinical Research

This pilot study will explore the usefulness of a series of questions asking about views of research from the perspective of minority and economically disadvantaged research participants. ...

Clinical Research in ALS

CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).

How Participants Perceive Biomedical Research in Pulmonology

The primary objective of this study is to determine how biomedical research is perceived by patients already participating in a pulmonology research project.

GenI: a Tool to Generate Paramedical Research Ideas

In order to develop paramedical research culture, the paramedical staff need adapted tools and methods. The GenI project (Research ideas generation) has for main objective the design and v...

Companies [1023 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...


Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...


The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "Lundbeck Research USA, Inc." on BioPortfolio

We have published hundreds of Lundbeck Research USA, Inc. news stories on BioPortfolio along with dozens of Lundbeck Research USA, Inc. Clinical Trials and PubMed Articles about Lundbeck Research USA, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Research USA, Inc. Companies in our database. You can also find out about relevant Lundbeck Research USA, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Corporate Database Quicklinks

Searches Linking to this Company Record